INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Appointment of Director
Resignation of Chief Financial Officer; Appointment of Principal Accounting Officer and Principal Financial Officer
On January 8, 2024, Kazia Therapeutics Limited (the “Company”) received notice from Karen Krumeich of her intention to resign as the Company’s Chief Financial Officer, effective immediately. Ms. Krumeich’s resignation is not the result of any disagreement between Ms. Krumeich and the Company, its management or board of directors, or related to the Company’s operations, policies or practices.
On January 11, 2024, the Company’s Board of Directors appointed Gabrielle Heaton as its Principal Accounting Officer and Principal Financial Officer, effective January 15, 2024. Ms. Heaton’s annual base compensation will be AUD $248,000.
Ms. Krumeich will remain with the Company in an advisory role for a period of time to be mutually agreed between her and the Company to support the transition.
Ms. Heaton currently serves as the Company’s Vice President of Finance and Administration. She has over 20 years of commercial experience in healthcare and biotech for multinational, ASX listed and overseas companies. She has held several senior Finance positions including CFO, Quality Auditor and been responsible for Human Resources and IT. Ms. Heaton has a Bachelor of Business from the University of Technology and is a member of CPA Australia.
The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form F-3 (File Nos. 333-259224 and 333-276091).
